Skip to main content
    T

    Tyra Biosciences Inc (TYRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.74
    -0.28 (-1.42%)

    Market Cap: $1.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tyra Biosciences Inc (TYRA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Tyra Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$119.95M, operating cash flow was -$95.14M and free cash flow was -$95.28M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$51.12M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $132.76M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$0$0$8.00K
    Gross profit$0$0$0$0$0$0-$8.00K
    Research and development$102.93M$80.08M$62.52M$43.01M$20.64M$7.20M$1.79M
    Operating income-$132.76M-$104.18M-$79.94M-$58.93M-$26.29M-$9.30M-$3.12M
    Net income-$119.95M-$86.48M-$69.13M-$55.33M-$26.29M-$9.34M-$4.06M
    EBITDA-$132.22M-$103.66M-$79.59M-$58.68M-$26.17M-$9.29M-$3.11M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$496.00K$0$0$0$502.00K
    Gross profit$0$0$0-$132.00K$0$0$0$248.00K$0$0$0$400.00K
    Operating income-$54.88M-$49.00M-$42.00M-$36.52M-$32.94M-$31.45M-$31.85M-$29.72M-$28.60M-$23.53M-$22.32M-$25.63M
    Net income-$51.12M-$45.56M-$39.30M-$33.83M-$29.87M-$28.10M-$28.15M-$25.57M-$24.02M-$18.70M-$18.19M-$22.83M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $472.00K by $76.92M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$282.61M$363.56M$225.86M$266.18M$306.70M$16.01M$528.00K
    Current assets$265.45M$347.46M$211.67M$257.29M$304.06M$15.28M$127.00K
    Cash and equivalents$77.39M$91.97M$58.01M$251.21M$302.18M$15.22M$108.00K
    Total liabilities$23.43M$20.41M$21.59M$8.35M$4.96M$2.00M$5.27M
    Short-term debt$472.00K$412.00K$280.00K$140.00K$202.00K$142.00K$139.00K
    Shareholder equity$259.18M$343.15M$204.26M$257.83M$301.74M-$13.64M-$4.74M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$727.53M$383.36M$412.04M$282.61M$301.85M$321.50M$343.48M$363.56M$380.59M$392.46M$404.74M$225.86M
    Total liabilities$34.68M$29.70M$24.46M$23.43M$21.34M$19.35M$19.94M$20.41M$18.30M$16.42M$14.86M$21.59M
    Cash and equivalents$456.02M$73.83M$84.95M$77.39M$61.95M$98.49M$100.72M$91.97M$103.89M$99.49M$254.37M$58.01M
    Shareholder equity$692.84M$353.66M$387.57M$259.18M$280.51M$302.15M$323.53M$343.15M$362.29M$376.04M$389.88M$204.26M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$95.14M-$69.77M-$50.14M-$50.28M-$23.75M-$7.76M-$2.62M
    Capital expenditures$141.00K$664.00K$770.00K$559.00K$661.00K$312.00K$20.00K
    Free cash flow-$95.28M-$70.44M-$50.91M-$50.84M-$24.41M-$8.07M-$2.64M
    Investing cash flow$72.46M-$98.40M-$144.60M-$559.00K-$645.00K-$312.00K-$20.00K
    Financing cash flow$8.10M$202.14M$1.54M$632.00K$311.35M$23.43M$157.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$32.21M-$31.08M-$32.57M-$23.62M-$22.38M-$23.68M-$25.46M-$19.59M-$17.90M-$10.26M-$22.03M-$13.53M
    Capital expenditures$90.00K$66.00K$88.00K$57.00K$39.00K$31.00K$14.00K$6.00K$52.00K$470.00K$136.00K$603.00K
    Free cash flow-$32.30M-$31.14M-$32.66M-$23.68M-$22.42M-$23.71M-$25.47M-$19.60M-$17.95M-$10.73M-$22.16M-$14.13M
    Last 12 quarters

    Frequently Asked Questions About TYRA

    What is Tyra Biosciences' annual revenue?

    Tyra Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Tyra Biosciences profitable?

    No. Tyra Biosciences reported net income of -$119.95M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TYRA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$95.14M minus capital expenditures of $141.00K produced free cash flow of -$95.28M.

    How much debt does Tyra Biosciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $472.00K and cash and equivalents of $77.39M.